domenica, 7 luglio 2024
Medinews

Uncategorized

27 Febbraio 2020

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

The outcome of patients with macroscopic stage III melanoma is poor. Neoadjuvant treatment with ipilimumab plus nivolumab at the standard dosing schedule induced pathological responses in a high proportion of patients in two small independent early-phase trials, and no ...
Leggi tutto
20 Febbraio 2020

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!